Oct 22, 2026 8:45am EDT RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Oct 07, 2026 8:30am EDT RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Oct 01, 2026 8:30am EDT RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
Sep 02, 2026 8:30am EDT RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
Aug 25, 2026 8:30am EDT RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
Aug 20, 2026 8:30am EDT RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
Aug 12, 2026 4:05pm EDT RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Aug 11, 2026 8:30am EDT RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
Aug 06, 2026 8:30am EDT RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
